Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Painful Diabetic Neuropathy Clear all
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 7, 2026, 7:23 AM EDT
Terminated No phase listed Observational

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

NCT01280747
View directory record Official record
Conditions
Fibromyalgia, Painful Diabetic Peripheral Neuropathy
Interventions
prior authorization, no prior authorization
Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Beverly Hills, California • Lomita, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 7, 2026, 7:23 AM EDT
Withdrawn Not applicable Interventional

Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy

NCT05041816
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Focal vibration therapy
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
45 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 7, 2026, 7:23 AM EDT
Enrolling by invitation Not applicable Interventional

Efficacy and Feasibility of BurstDR SCS in Painful Diabetic Neuropathy

NCT07250828
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain
Interventions
BurstDR Spinal Cord Stimulation
Device
Lead sponsor
TriCity Research Center
Industry
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Grand Island, Nebraska
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 7, 2026, 7:23 AM EDT
Not listed Phase 4 Interventional

Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy

NCT00123136
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
foot energizer
Device
Lead sponsor
Weintraub, Michael I., MD, FACP, FAAN
Individual
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Briarcliff, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Oct 7, 2026, 7:23 AM EDT
Not listed Phase 2 Interventional

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

NCT04679545
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD, Placebo
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomfield Township, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 7, 2026, 7:23 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial

NCT04087941
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
VM-202
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

NCT01521598
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
SKL11197, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Northport, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 7, 2026, 7:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Peer Support for Patients With Diabetic Foot Ulcers

NCT06004219
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Wound, Diabetes Mellitus, Type 2, Diabetic Foot, Diabetes Complications, Peripheral Neuropathy
Interventions
Peer counseling group
Behavioral
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Downey, California • Los Angeles, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 7, 2026, 7:23 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

NCT02215252
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 7, 2026, 7:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain

NCT01620775
View directory record Official record
Conditions
Chronic Low Back Pain, Diabetic Peripheral Neuropathy, Knee Osteoarthritis
Interventions
MRIs, Pain testing
Other
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - ENRGy2 Addendum

NCT01764373
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Aerobic Exercise
Other
Lead sponsor
University of Kansas
Other
Eligibility
40 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management

NCT05620225
View directory record Official record
Conditions
Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy
Interventions
Axon Therapy and CMM, Sham and CMM
Device
Lead sponsor
NeuraLace Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Sebastian, Florida • St. Petersburg, Florida • Vero Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 4 Interventional

Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain

NCT00266643
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • Tallahassee, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2007 · Synced Oct 7, 2026, 7:23 AM EDT
Active, not recruiting Not applicable Interventional

PDN Post Market, Multicenter, Prospective, Global Clinical Study

NCT05301816
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Spinal Cord Stimulator (SCS)
Device
Lead sponsor
Nevro Corp
Industry
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Anchorage, Alaska • Ann Arbor, Michigan • West Bloomfield, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 7, 2026, 7:23 AM EDT
Terminated Phase 4 Interventional Results available

Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

NCT01743976
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

NCT00857623
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Bella Vista, Arkansas • National City, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 4 Interventional

An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

NCT00194909
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
sildenafil (Viagra)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 7, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

NCT00993018
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Jonesboro, Arkansas • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 7, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors

NCT00010751
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Reiki
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 7, 2026, 7:23 AM EDT